SG11201909011PA - Niraparib compositions - Google Patents

Niraparib compositions

Info

Publication number
SG11201909011PA
SG11201909011PA SG11201909011PA SG11201909011PA SG 11201909011P A SG11201909011P A SG 11201909011PA SG 11201909011P A SG11201909011P A SG 11201909011PA SG 11201909011P A SG11201909011P A SG 11201909011PA
Authority
SG
Singapore
Prior art keywords
international
rule
niraparib
tesaro
waltham
Prior art date
Application number
Inventor
George Wu
John Chaber
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of SG11201909011PA publication Critical patent/SG11201909011PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT omit im iflo oimIE (10) International Publication Number WO 2018/183354 Al (51) International Patent Classification: A61K 31/454 (2006.01) C07D 401/10 (2006.01) (21) International Application Number: PCT/US2018/024603 (22) International Filing Date: Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/477,411 27 March 2018 (27.03.2018) English English 27 March 2017 (27.03.2017) US (71) Applicant: TESARO, INC. [US/US]; 1000 Winter St. North #3300, Waltham, Massachusetts 02451 (US). (72) Inventors: WU, George; c/o Tesaro, Inc., 1000 Winter St. North #3300, Waltham, Massachusetts 02451 (US). CHABER, John; c/o Tesaro, Inc., 1000 Winter St. North #3300, Waltham, Massachusetts 02451 (US). (74) Agent: MCANDREW, Christopher W.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, Cali- fornia 94304 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(0) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) 00 1-1 00 O \" (57) : The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of 0 niraparib. (54) Title: NIRAPARIB COMPOSITIONS
SG11201909011P 2017-03-27 2018-03-27 Niraparib compositions SG11201909011PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762477411P 2017-03-27 2017-03-27
PCT/US2018/024603 WO2018183354A1 (en) 2017-03-27 2018-03-27 Niraparib compositions

Publications (1)

Publication Number Publication Date
SG11201909011PA true SG11201909011PA (en) 2019-10-30

Family

ID=63676949

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909011P SG11201909011PA (en) 2017-03-27 2018-03-27 Niraparib compositions

Country Status (14)

Country Link
US (3) US11091459B2 (en)
EP (1) EP3600314A1 (en)
JP (1) JP2020512350A (en)
KR (1) KR20200014736A (en)
CN (1) CN110944638A (en)
AU (2) AU2018246214B2 (en)
BR (1) BR112019020211A2 (en)
CA (1) CA3058375A1 (en)
EA (1) EA201992177A1 (en)
IL (1) IL269630A (en)
MX (1) MX2019011496A (en)
SG (1) SG11201909011PA (en)
TW (1) TWI761476B (en)
WO (1) WO2018183354A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020512350A (en) 2017-03-27 2020-04-23 テサロ， インコーポレイテッド Nilaparib composition
TWI783993B (en) 2017-04-24 2022-11-21 美商提薩羅有限公司 Methods of manufacturing of niraparib
JP2020520921A (en) 2017-05-18 2020-07-16 テサロ， インコーポレイテッド Combination therapy to treat cancer
EP3687505A1 (en) 2017-09-26 2020-08-05 Tesaro Inc. Niraparib formulations
SG11202002862RA (en) 2017-09-30 2020-04-29 Tesaro Inc Combination therapies for treating cancer
MX2020003799A (en) 2017-10-06 2020-11-06 Tesaro Inc Combination therapies and uses thereof.
CA3090479A1 (en) 2018-02-05 2019-08-08 Tesaro, Inc Pediatric niraparib formulations and pediatric treatment methods
WO2020072860A1 (en) * 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Niraparib solid state form
CA3087392A1 (en) 2019-07-16 2021-01-16 Apotex Inc. Crystalline forms of niraparib tosylate
CA3177094A1 (en) 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Treatment of prostate cancer with a combination of abiraterone acetate and niraparib
WO2023001746A1 (en) 2021-07-19 2023-01-26 Janssen Pharmaceutica Nv Treatment of metastatic castration-resistant prostate cancer with niraparib
WO2023159066A1 (en) 2022-02-15 2023-08-24 Tesaro, Inc. Use of niraparib for the treatment of brain cancer
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
WO2023233295A1 (en) 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113596A1 (en) 2006-04-03 2007-10-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
GB0606663D0 (en) 2006-04-03 2006-05-10 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008043024A2 (en) 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
EP2109608B1 (en) * 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
KR101598231B1 (en) * 2007-10-17 2016-02-26 쿠도스 파마슈티칼스 리미티드 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
CN106008460B (en) * 2008-01-08 2022-08-12 默沙东公司 Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
UA110604C2 (en) * 2009-08-26 2016-01-25 Сефалон, Інк. Crystalline form of polycyclic compounds
CA2779052A1 (en) 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
EP2928473B1 (en) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
DK2928865T3 (en) 2012-12-07 2018-06-18 Merck Sharp & Dohme BIOCATALYTIC TRANSAMINATION PROCEDURE
JP2016519684A (en) 2013-04-08 2016-07-07 デニス エム ブラウン Methods and compositions for improving the efficacy of suboptimally administered medication and / or reducing side effects
US9191894B2 (en) * 2013-07-23 2015-11-17 Disney Enterprises, Inc. Power saving for multi-hop communications
EP3089965B1 (en) 2014-01-05 2018-08-29 Washington University Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
US20150299219A1 (en) 2014-04-22 2015-10-22 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
JP6648040B2 (en) 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Use of eribulin and poly (ADP-ribose) polymerase (PARP) inhibitors as combination therapy for cancer treatment
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
EP3230472A4 (en) 2014-12-08 2018-06-13 Myriad Genetics, Inc. Methods and materials for predicting response to niraparib
MA50817B1 (en) 2015-07-02 2021-10-29 Acerta Pharma Bv Forms and solid formulations of (s) -4- (8-amino-3- (1- (but-2-ynoyl) pyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -n - (pyridin-2-yl) benzamide
EP4302835A3 (en) * 2016-06-29 2024-03-20 Tesaro, Inc. Methods of treating ovarian cancer
CN106496187A (en) * 2016-09-14 2017-03-15 陕西科技大学 A kind of synthetic method for preparing PARP inhibitor Niraparib
CN106831708A (en) 2016-11-22 2017-06-13 西安泰科迈医药科技股份有限公司 A kind of synthetic method of new oral cancer therapy drug Nirapairb
CN108201537A (en) 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 A kind of Ni Lapani sustained and controlled release medicaments composition and application thereof
CN106854176A (en) 2016-12-21 2017-06-16 南京艾德凯腾生物医药有限责任公司 A kind of method for preparing Ni Lapani tosilate monohydrates
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
JP2020512350A (en) 2017-03-27 2020-04-23 テサロ， インコーポレイテッド Nilaparib composition
KR20190130625A (en) 2017-03-27 2019-11-22 테사로, 인코포레이티드 Niraprip formulation
TWI783993B (en) 2017-04-24 2022-11-21 美商提薩羅有限公司 Methods of manufacturing of niraparib
MA48637A (en) 2017-05-09 2021-03-17 Merck Sharp & Dohme POLYTHERAPIES FOR THE TREATMENT OF CANCER
JP2020520921A (en) 2017-05-18 2020-07-16 テサロ， インコーポレイテッド Combination therapy to treat cancer
CN108530425A (en) 2017-05-27 2018-09-14 广州科锐特生物科技有限公司 A kind of Ni Lapani tosilate hydrate crystal forms and preparation method thereof
EP3687505A1 (en) 2017-09-26 2020-08-05 Tesaro Inc. Niraparib formulations
SG11202002862RA (en) 2017-09-30 2020-04-29 Tesaro Inc Combination therapies for treating cancer
MX2020003799A (en) 2017-10-06 2020-11-06 Tesaro Inc Combination therapies and uses thereof.
CN111801117A (en) 2017-12-27 2020-10-20 特沙诺有限公司 Methods of treating cancer
CA3090479A1 (en) 2018-02-05 2019-08-08 Tesaro, Inc Pediatric niraparib formulations and pediatric treatment methods

Also Published As

Publication number Publication date
KR20200014736A (en) 2020-02-11
TW201840315A (en) 2018-11-16
WO2018183354A1 (en) 2018-10-04
AU2018246214A1 (en) 2019-11-07
EA201992177A1 (en) 2020-02-25
BR112019020211A2 (en) 2020-04-22
MX2019011496A (en) 2020-01-23
AU2021245223A1 (en) 2021-11-04
US20230416223A1 (en) 2023-12-28
EP3600314A1 (en) 2020-02-05
US11091459B2 (en) 2021-08-17
CA3058375A1 (en) 2018-10-04
IL269630A (en) 2019-11-28
TWI761476B (en) 2022-04-21
US20200017462A1 (en) 2020-01-16
US20210403448A1 (en) 2021-12-30
JP2020512350A (en) 2020-04-23
AU2018246214B2 (en) 2021-07-08
CN110944638A (en) 2020-03-31
US11673877B2 (en) 2023-06-13

Similar Documents

Publication Publication Date Title
SG11201909011PA (en) Niraparib compositions
SG11201906200WA (en) Nucleic acid-polypeptide compositions and methods of inducing exon skipping
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201909432SA (en) Compounds for increasing genome editing efficiency
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201901531TA (en) Regulation of gene expression using engineered nucleases
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201808990QA (en) Compositions for topical application of compounds
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201900844UA (en) Amino pyrimidine ssao inhibitors
SG11201811643TA (en) Compounds and methods for modulating rna function
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201806267QA (en) Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers